Meta AnalysisID 6226
指南推荐的中成药对糖尿病前期患者血脂影响的比较疗效：网状Meta分析
CRD42021279332
The aim of this meta-analysis of randomized controlled trials is to evaluate the efficacy and safety of adjunctive Traditional Chinese Patent Medicines recommended from guidelines for blood lipids in patients with predia
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6226
- Evidence Id
- 14784
- Core Evidence Id
- 14784
- Source Meta Analysis Id
- 6207
- Herb2 Meta Analysis Id
- HBMA006207
- Crd Id
- CRD42021279332
- Title
- Comparative Efficacy of Traditional Chinese Patent Medicines Recommended from Guidelines for Blood Lipids in Patients with prediabetes: A network meta-analysis
- Review Question
- The aim of this meta-analysis of randomized controlled trials is to evaluate the efficacy and safety of adjunctive Traditional Chinese Patent Medicines recommended from guidelines for blood lipids in patients with prediabetes.
- Study Type Included
- Randomized clinical trials will be included irrespective of blinding, publication status or language
- Condition Being Studied
- Prediabetes is a state of abnormal glucose metabolism between normal blood glucose and diabetes, including impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) or both (IFG+IGT). Dyslipidemia is a high risk factor to increase the incidence of cardiovascular complications in diabetes mellitus, and an independent risk factor to induce coronary atherosclerosis. Clinical studies have shown that Traditional Chinese Patent Medicines had the unique superiority in improving blood lipid status for prediabetes and relieving symptoms. Domestic and western guidelines for prediabetes have clearly recommended several kinds of Traditional Chinese Patent Medicines. Although there were meta-analyses on the clinical efficacy of Traditional Chinese Patent Medicines in the treatment of prediabetes, the following shortcomings still existed: (1) The main focus is on blood glucose indicators, such as Hba1c, FBG and PBG, and there was a lack of sufficient attention to blood lipids. (2) The number of included literatures was small, the sample size was insufficient, and the heterogeneity among different comparisons was large; (3) Most studies only reported the direct comparison between Chinese patent medicine and western medicine or placebo, and there was still a lack of efficacy comparison between various types of Chinese patent medicines.
- Participant
- inclusion criteria : (1) types of studies: randomized controlled trials (RCTs); (2) type of participants: patients diagnosed with prediabetes. (3) Main intervention: The control group was treated with oral hypoglycemic drugs or LM, while the experimental group was treated with LM combined with CTPM, including Shen qi jiang tang capsule/granule/tablet, Tian mai xiao ke capsule/granule/table, Tian qi capsule/ granule/tablet, Jin qi jiang tang capsule/granule/table, Jin li da capsule/granule/table, Tang mai kang capsule/granule/tablet. (4) Intervention time of clinical studies that included HbA1c was longer than 12 weeks to meet the base time for the change of HbA1c. (5) Outcomes: blood lipids, including triglyceride(TG)、total cholesterol (TC)、low-density lipoprotein cholesterol(LDL-C)、high-density lipoprotein cholesterol(HDL-C) exclusion criteria: (1) The intervention of the experimental group was decoctions, herbal extracts, or other synthetic plant-based drugs; (2) In the experimental group, the intervention was combined with oral hypoglycemic drugs or other Chinese herbal medicines or appropriate technology of TCM, such as acupuncture, point application therapy and massage; (3) Unknown dosage of intervention drugs and unmatched composition of prescription; (4) Studies with incomplete general data and baseline indicators. (5) Observational studies, repeated publications and studies without full text.
- Animal
- Human Disease Modelled
- Intervention
- The experimental group was treated with LM combined with CTPM, including Shen qi jiang tang capsule/granule/tablet, Tian mai xiao ke capsule/granule/table, Tian qi capsule/ granule/tablet, Jin qi jiang tang capsule/granule/table, Jin li dacapsule/granule/table, Tang mai kang capsule/granule/tablet. The authors defined TCPM as refined dosage forms, such as capsules, tablets, oral liquid, and powders, which originated from herbal medicine (whole plants or their adjuncts), relative standardization in composing the main effective components, and manufactured in accordance with the PRC Pharmacopoeia’s monograph.
- Comparator Control
- The control group was treated with oral hypoglycemic drugs or LM. The two groups maintained the same baseline in basic characteristics, routine treatment measures (health education, diet control, antihypertensive drugs, lipid-lowering drugs), course of treatment, and related indicators before treatment.
- Main Outcome
- triglyceride(TG)、total cholesterol (TC)、low-density lipoprotein cholesterol(LDL-C)、high-density lipoprotein cholesterol(HDL-C) Measures of effect SMD
- Outcome Measure
- Additional Outcome
- Not applicable
- Study Method
- Intervention, Network meta-analysis, Systematic review
- Keyword
- China; Humans; Lipids; Network Meta-Analysis; Nonprescription Drugs; Prediabetic State
- Contact
- Li Jiang [email protected]
- Organisational Affiliation
- Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, Beijing, China
- Funding Source
- This work was supported by grants from The General Project of National Natural Science Foundation of China， Project for Young Teachers of Beijing University of Chinese Medicine and National Key R&D Program of China and the Project of Beijing Science and Technology Subject Grant number(s) <span style=font-size: 14px>State the funder, grant or award number and the date of award</span> No. 81774272, No.2019-JYB-JS-080，No：2018YFC1704400，No：2018YFC1704402，Z191100008319004
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2021-09-17
- Registration Date
- 2021-10-19
- Anticipated Start Date
- 2021-08-31
- Anticipated Completion Date
- 2021-10-17
- Title Cn
- 指南推荐的中成药对糖尿病前期患者血脂影响的比较疗效：网状Meta分析
- Title En
- Comparative Efficacy of Traditional Chinese Patent Medicines Recommended from Guidelines for Blood Lipids in Patients with prediabetes: A network meta-analysis
- Bilingual Status
- complete